6533b86ffe1ef96bd12cd263
RESEARCH PRODUCT
Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium
Renate B. SchnabelPhilipp S. WildTorben JørgensenPaul M. RidkerKarl J. LacknerPaolo BrambillaTanja ZellerWolfgang KoenigWolfgang KoenigGiovanni VeronesiKuulasmaa KariVeikko SalomaaFrancisco OjedaNataliya MakarovaErkki VartiainenB ThorandLicia IacovielloBrendan M. EverettBlankenberg StefanGerard J. LindenChristopher PattersonAstrid PetersmannJukka KonttoMatthias NauckSimona CostanzoJohn YarnellAnnette PetersFrank Keesubject
Relative risk reductionPathologymedicine.medical_specialtyBIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICAPopulationBiomarker For Cardiovascular Risk Assessment In Europe ; Cardiovascular Risk ; High-sensitivity Assayed Troponin I ; Monica Risk Genetics Archiving And Monograph ; Mortality030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingInternal medicineTroponin IMedicineRosuvastatin030212 general & internal medicineMortalityeducationBiomarker for Cardiovascular Risk Assessment in Europe; Cardiovascular risk; High-sensitivity assayed troponin I; MONICA Risk Genetics Archiving and Monograph; Mortalityeducation.field_of_studyFramingham Risk Scorebiologybusiness.industryHazard ratioAbsolute risk reductionBiomarker for Cardiovascular Risk Assessment in EuropeCardiovascular riskMONICA Risk Genetics Archiving and MonographTroponinHigh-sensitivity assayed troponin I3. Good healthCardiologybiology.protein/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingCardiology and Cardiovascular Medicinebusinessmedicine.drugdescription
AIMS: Our aims were to evaluate the distribution of troponin I concentrations in population cohorts across Europe, to characterize the association with cardiovascular outcomes, to determine the predictive value beyond the variables used in the ESC SCORE, to test a potentially clinically relevant cut-off value, and to evaluate the improved eligibility for statin therapy based on elevated troponin I concentrations retrospectively.METHODS AND RESULTS: Based on the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) project, we analysed individual level data from 10 prospective population-based studies including 74 738 participants. We investigated the value of adding troponin I levels to conventional risk factors for prediction of cardiovascular disease by calculating measures of discrimination (C-index) and net reclassification improvement (NRI). We further tested the clinical implication of statin therapy based on troponin concentration in 12 956 individuals free of cardiovascular disease in the JUPITER study. Troponin I remained an independent predictor with a hazard ratio of 1.37 for cardiovascular mortality, 1.23 for cardiovascular disease, and 1.24 for total mortality. The addition of troponin I information to a prognostic model for cardiovascular death constructed of ESC SCORE variables increased the C-index discrimination measure by 0.007 and yielded an NRI of 0.048, whereas the addition to prognostic models for cardiovascular disease and total mortality led to lesser C-index discrimination and NRI increment. In individuals above 6 ng/L of troponin I, a concentration near the upper quintile in BiomarCaRE (5.9 ng/L) and JUPITER (5.8 ng/L), rosuvastatin therapy resulted in higher absolute risk reduction compared with individuals <6 ng/L of troponin I, whereas the relative risk reduction was similar.CONCLUSION: In individuals free of cardiovascular disease, the addition of troponin I to variables of established risk score improves prediction of cardiovascular death and cardiovascular disease.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2016-08-07 | European Heart Journal |